<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MEFLOQUINE HYDROCHLORIDE</span><br/>(me-flo'quine)<br/><span class="topboxtradename">Lariam<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antimalarial</span><br/><b>Prototype: </b>Chloroquine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Antimalarial agent, structurally related to quinine.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against all types of malaria, including chloroquine resistant malaria.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of mild to moderate acute malarial infections, prevention of chloroquine-resistant malaria caused by <i>Plasmodium falciparum</i> and <i>P. vivax.</i>
</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to mefloquine or a related compound; with a calcium channel blocking agent, severe heart arrhythmias, history
         of QTc prolongation; aggressive behavior; active depression, or history of depression, suicidal ideation; generalized anxiety
         disorder, psychosis, schizophrenia, or other major psychiatric disorders; seizure disorders; pregnancy (category C); infancy.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation; persons piloting aircraft or operating heavy machinery. Safety and efficacy in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td>
<p>
                  				Note: FDA has <small>NOT</small> approved use of mefloquine in children, and the U.S. Public Health Service does <small>NOT</small> recommend its use in children <span class="indicationtitle">Treatment of Malaria</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1250 mg (5 tablets) as single oral dose taken with at least 8 oz of water<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 2030 mg/kg as single dose<br/><br/><span class="indicationtitle">Prophylaxis for Malaria</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250 mg once/wk <small>x</small> 4 wk (beginning 1 wk before travel), then 250 mg every other wk for duration of exposure and
               for 2 doses after leaving endemic area<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>1519 kg,</i> <small>1/4</small> tablet; <i>2030 kg,</i> ½ tablet; <i>3145 kg,</i> ¾ tablet<br/></p></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food and at least 8 oz water.</li>
<li>Do not give concurrently with quinine or quinidine; wait at least 12 h beyond last dose of either drug before administering
            mefloquine.
         </li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Arthralgia, chills, fatigue, fever. <span class="typehead">CNS:</span> Dizziness, nightmares, visual disturbances, headache, syncope, confusion, psychosis, aggression, suicide ideation (rare). <span class="typehead">CV:</span> Bradycardia, ECG changes (including QTc prolongation), first-degree AV block. <span class="typehead">GI:</span> Nausea, vomiting, abdominal pain, anorexia, diarrhea. <span class="typehead">Skin:</span> Rash, itching. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Transient increase in liver transaminases.</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Mefloquine can prolong cardiac conduction in patients taking <span class="classification">beta blockers</span>, <span class="classification">calcium channel blockers</span>, and possibly <b>digoxin.</b>
<b>Quinine</b> may decrease plasma mefloquine concentrations. Mefloquine may decrease <b>valproic acid</b> serum concentrations by increasing its hepatic metabolism. Administration with <b>chloroquine</b> may increase risk of seizures. Increased risk of cardiac arrest and seizures with <b>quinidine.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 85% absorbed, concentrates in red blood cells. <span class="typehead">Onset:</span> 59 and 28 h for parasite and fever clearance times in patients with <i>P. vivax</i> infections, respectively; 166 and 93 h in patients with <i>P. malariae</i> infections. <span class="typehead">Distribution:</span> Concentrated in red blood cells due to high-affinity binding to red blood cell membranes; 98% protein bound; distributed
      minimally into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Eliminated primarily in bile and feces. <span class="typehead">Half-Life:</span> 1021 d (shorter in patients with acute malaria). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor carefully during prophylactic use for development of unexplained anxiety, depression, restlessness, or confusion;
            such manifestations may indicate a need to discontinue the drug.
         </li>
<li>Evaluate cardiac and liver functions periodically with prolonged use.</li>
<li>Lab tests: Monitor periodically CBC with differential during prolonged use.</li>
<li>Monitor blood levels of anticonvulsants with concomitant therapy closely.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take drug on the same day each week when used for malaria prophylaxis.</li>
<li>Do not perform potentially hazardous activities until response to drug is known.</li>
<li>Report any of the following immediately: Fever, sore throat, muscle aches, visual problems, anxiety, confusion, mental depression,
            hallucinations.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>